The Defense Threat Reduction Agency (DTRA), with industry and government partners, has been working aggressively for the past decade to understand and counter Zaire ebolavirus (EBOV).
DTRA’s program is currently supporting the accelerated development of a therapeutic through preclinical Investigational New Drug (IND) enabling activities as well as the clinical evaluation for one EBOV vaccine.
The program co-developed the rapid field deployable diagnostic systems currently in use in West Africa. The program has also been adapting and improving upon North Atlantic Treaty Organization (NATO) approved and high performance computing methods of modeling EBOV to perform analysis of the current EBOV outbreak.
Recognizing that industry may have solutions applicable to the current EBOV outbreak in West Africa, DTRA has release a new BAA to ensure that all potential near-term solutions are considered.
The primary objective of this BAA is to support development of near-term solutions such as therapeutic and vaccine candidates; diagnostic capabilities; modeling capabilities; and data gaps.
For medical countermeasures, only late stage development products for EBOV that can be completed and implemented in the near-term; defined as in time to assist with the current EBOV outbreak will be considered under this solicitation.
Further details are available via Solicitation Number: HDTRA1-15-EBOLA-BAA. The BAA will expire on March 31, 2015.